89. The use of psychedelics in the treatment of depression: a closer look at psilocybin, mebufotenin, and ayahuasca

In a previous blog, https://addictionsandrecoverydotblog.com/2024/10/23/38-are-hallucinogens-psychedelics-addictive/, we looked at the effects of psychedelics and how some might be used for the treatment of mental disorders. We revisit that theme here.

Distressed person sitting alone on an unmade bed in a messy bedroom
An AI-generated image of a distressed person sits alone on an unmade bed as rain blurs the city outside.

First, what is depression, or specifically, Major Depressive Disorder (MDD)?

According to https://www.healthcentral.com/condition/depression/dsm-5-depression-criteria, depression, or more specifically, Major Depressive Disorder (MDD), is defined as a common and serious mood disorder. Those who suffer from depression experience persistent feelings of sadness and hopelessness and lose interest in activities they once enjoyed. Aside from the emotional problems caused by depression, individuals can also present with a physical symptom such as chronic pain or digestive issues. To be diagnosed with depression, symptoms must be present for at least two weeks.

The DSM-5 states that to make a diagnosis of depression, the individual must be experiencing five or more symptoms during the same 2-week period and at least one of the symptoms should be either (1) depressed mood or (2) loss of interest or pleasure:

  1. Depressed mood most of the day, nearly every day.
  2. Markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day.
  3. Significant weight loss when not dieting or weight gain, or decrease or increase in appetite nearly every day.
  4. A slowing down of thought and a reduction of physical movement (observable by others, not merely subjective feelings of restlessness or being slowed down).
  5. Fatigue or loss of energy nearly every day.
  6. Feelings of worthlessness or excessive or inappropriate guilt nearly every day.
  7. Diminished ability to think or concentrate, or indecisiveness, nearly every day.
  8. Recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for committing suicide.

How is depression treated?

Depression is treated with both psychotherapy and with medicines (pharmacological approach).

Psychotherapy

There are several well-established psychological therapies for depression. The best choice depends on what is contributing to the depression, the person’s preferences, and whether the depression is mild, moderate, or severe. The American Psychological Association considers several approaches evidence-based for adults. https://www.apa.org

Main therapies

  1. Cognitive Behavioral Therapy (CBT)
    • One of the most widely used treatments.
    • Helps identify negative or distorted thoughts and change behaviors that maintain depression.
    • Particularly useful for thoughts such as “I’m a failure,” “nothing will change,” or “there’s no point in trying.”
    • Usually structured and relatively short-term. https://www.apa.org
  2. Behavioral Activation
    • Especially useful when depression leads to withdrawal, inactivity, and loss of pleasure.
    • The therapist helps the person gradually resume meaningful, enjoyable, and rewarding activities—even before motivation returns.
    • It is an evidence-based treatment in its own right. https://www.apa.org
  3. Interpersonal Psychotherapy (IPT)
    • Focuses on relationships and life changes that may be contributing to depression.
    • Particularly helpful with bereavement, loneliness, relationship conflicts, retirement or other role changes, and communication difficulties.
    • Usually short-term. https://www.apa.org
  4. Psychodynamic Therapy
    • Looks more deeply at recurring emotional and relationship patterns, including the influence of earlier experiences.
    • Can be particularly appropriate when depression is connected to loss, longstanding self-criticism, relationship patterns, or unresolved emotional conflicts.
    • Can be short- or longer-term. https://www.apa.org
  5. Supportive Therapy
    • Emphasizes a strong, supportive therapeutic relationship.
    • Helps a person cope with current stresses, make decisions, and develop more effective ways of handling difficulties.
    • Can be especially useful when someone needs emotional support and practical coping assistance. https://www.apa.org
  6. Mindfulness-Based Cognitive Therapy (MBCT)
    • Combines CBT with mindfulness.
    • Particularly useful for learning to recognize depressive thoughts without automatically accepting them as facts.
    • Has an important role in reducing the risk of recurrent depression. https://www.apa.org
  7. Problem-Solving Therapy
    • Helps a person break overwhelming life problems into manageable steps and develop concrete solutions.
    • Can be particularly useful when depression is accompanied by significant practical life stresses. nhs.uk

Which might be best?

A simple way to think about it:

If the main problem is…Therapy to consider
Negative thinking, hopelessness, self-criticismCBT
Withdrawal, inactivity, loss of interestBehavioral Activation
Loneliness, grief, relationship problemsIPT
Longstanding emotional/relationship patternsPsychodynamic therapy
Feeling overwhelmed by practical problemsProblem-solving therapy
Recurrent depression and getting caught in negative thoughtsMBCT
Need for support and coping with current circumstancesSupportive therapy

Pharmacological approach

The pharmacological approach focuses on enhancing the activity of serotonin, the neurotransmitter found in parts of the brain which control our mood, such as the limbic system.

The following infographic summarizes the cycle by which serotonin is released by the presynaptic cell, travels across the synapse to bind with receptors on the postsynaptic cell, and then is taken back up by the presynaptic cell:

Most medications used in the treatment of depression cause serotonin molecules to persist in the synapse a little longer by inhibiting their reuptake back into the presynaptic cell. Selective serotonin reuptake inhibitors (SSRIs such as Lexapro, Zoloft, Paxil and Prozac) and Serotonin-norepinephrine reuptake inhibitors (SNRIs such as Cymbalta, Effexor XR and Fetzima) do just that.

What options does a patient have when (s)he has depression resistant to treatment?

In recent years, a considerable amount of research has been devoted to exploring how psychedelics, particularly psilocybin, mebufotenin, and LSD, can be used to treat medication-resistant depression.

There are considerable similarities in the chemical structures of psilocin (the active ingredient derived from psilocybin) and mebutotenin to serotonin. Notice the basic similarities in their chemical structures. All them share the same indole core.

Diagram comparing psilocin, serotonin, and mebufotenin structures and substitutions
A visual comparison highlights the shared indole core and key substitutions in psilocin, serotonin, and mebufotenin.

Psilocybin

In a previous blog, https://addictionsandrecoverydotblog.com/2023/12/12/13-therapeutic-applications-of-psilocybin/, we looked at possible therapeutic applications of psilocybin.

In that post, I stated that numerous diseased states are being explored in which psilocybin-assisted therapy may provide significant benefit and treatment, including the following:

  1. Alcohol, stimulant and cannabis dependence
  2. Addictions to cocaine, tobacco, nicotine, and opioids
  3. Anxiety disorders such as Post-traumatic stress disorder (PTSD), Generalized anxiety disorder (GAD), Obsessive-compulsive disorder
  4. Various forms of depression, such as Cancer-related, Treatment-resistant, Major Depressive Disorder, Severe existential depression
  5. Chronic and intractable phantom pain
  6. Epilepsy
  7. Borderline and Narcissistic Personality Disorders
  8. Psychopathy
  9. Emotional dysregulation and violence against one’s partner, and
  10. Inflammation

In this post, we will look at research focusing on the possible benefits of psilocybin, mebufotenin, and ayahuasca in the treatment of depression.

The natural source of psilocybin and related compounds, e.g. psilocin, are mushrooms, collectively called Magic Mushrooms, of the genus Psilocybe, which have an international distribution. The following image is from

Fruit bodies of the hallucinogenic mushroom Psilocybe semilanceata. Specimens photographed in Sweden. This image is Image Number 6154 at Mushroom Observer, a source for mycological images. Author: Arp.

When psilocybin is ingested, it is converted to psilocin, which is the compound that is actually psychoactive.

Psilocin binds to 5HT-2A serotonin receptors, which are abundant in parts of the brain which are responsible for the mediation of mood and anxiety disorders such as the pre-frontal cortex. Downstream signaling leads to decreased depression and anxiety.

For example, Yngwe, et. al. (2026) describe a double-blind, placebo-controlled, randomized clinical trial of 35 participants (21 female, 41.0 years) diagnosed with moderate-to-severe recurrent major depressive disorder (MDD) who received a single dose of psilocybin (25 mg) or active placebo (niacin, 100 mg) and 5 psychotherapeutic support sessions during 17 days. Investigators found that starting by day 2 and persisting for more than 3 months, psilocybin was associated with rapid antidepressant effects, as demonstrated in a significant reduction in Montgomery-Asberg Depression Rating Scale (MADRS).

There are some studies which suggest that the beneficial effects of psilocybin can be sustained for 6 to 12 months (Avram and Borgwardt, 2025)

Mebufotenin

Mebufotenin has several natural sources, including the Colorado River toad (Incilius alvarius), trees (Anadenanthera colubrina), and selected mushrooms:

In fact, humans produce small amounts of mebufotenin.

Like psilocybin, mebufotenin is a serotonin agonist, i.e., it enhances the effects of serotonin. Unlike psilocybin, the duration of its effects are relatively short, so its use presents some advantages in a clinical setting.

Feifel, et. al. (2026) report the results of a randomized, double-blind, phase 2b trial of single doses of 8-mg or 12-mg mebufotenin nasal spray, compared to 0.3 mg, a low-dose comparator) in 193 adults with treatment-resistant depression. The primary end point was total score change on the Montgomery-Asberg Depression Rating Scale (MADRS), in which higher scores indicate more severe depression. Each subject received a single spray into 1 nostril by a trained clinician, with >4 hours of observation accompanied by psychological support.

The investigators found that from baseline to day 29, treatment with either the 8-mg or 12-mg intranasal mebufotenin benzoate was associated with significantly reduced MADRS scores, compared to the 0.3-mg dose. MADRS reductions with the 8-mg and 12-mg doses were similar and significantly greater at all other time points from 2 to 57 days post dose vs. the 0.3-mg dose. Adverse events were, for the most part, mild or moderate.

Feifel et. al. conclude that single doses of intranasal mebufotenin benzoate were well tolerated and produced rapid, robust, and durable reductions in depressive symptoms. The shorter monitoring period and few clinic visits provided distinct advantages to treatment with psilocybin and esketamine.

Ayahuasca

Initial tests using ayahuasca, or more specifically, DMT (dimethyltryptamine) show similar promise in the treatment of major depressive disorder:

For example, conducted a phase IIa, double-blind, placebo-controlled, randomized clinical trial to evaluate the efficacy and safety of intravenous DMT in 34 adults with moderate-to-severe MDD. Seventeen of the participants Participants received a single 21.5-mg dose of DMT or placebo infused over 10 min, along with supportive psychotherapeutic support, followed by a 2-week assessment. A subsequent open-label phase offered all participants a second DMT dose. The primary outcome was the change in Montgomery–Åsberg Depression Rating Scale (MADRS) at 2 weeks. Secondary outcomes included response (≥50% reduction in MADRS score) and remission (MADRS ≤ 10). At 2 weeks, the DMT group showed a significantly greater reduction in MADRS score than placebo (mean
difference = −7.35; 95% CI = −13.62 to −1.08;
P = 0.023). In the open-label phase, AD effects persisted up to 3 months, with no significant differences between those who received one versus two doses. Adverse events were mostly mild to moderate, commonly infusion site pain, nausea and transient anxiety. No serious adverse events occurred. A single
dose of DMT with psychotherapeutic support produced a rapid, significant reduction in depressive symptoms, sustained up to 3 months. The treatment was well-tolerated and safe.

Avram, M.; Borgwardt, S. (2025). Psychedelics for major depression – From controlled research settings into roader clinical use. Cell Reports Medicine 6, 102361. https://doi.org/10.1016/j.xcrm.2025.102361.

Erritzoe, D.; Barba, T.; Benway, T.; Joel, Z.; Good, M.; Layzell, M.; Jones, M.B.; Campbell, G.; Murphy-Beiner, A.; Rands, R.; Boyce, M.; Topping, H.; Weiss, B.; Timmermann, C.; Nutt, D.; Carhart-Harris, R.; Routledge, C.; James. E. (2026).A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial. Nature Medicine 32: 591–598. https://doi.org/10.1038/s41591-025-04154-z

Feifel, D.; Seynaeve, M.; Wieslaw, J.C.; et. al. (2026). Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression: A Randomized Clinical Trial. Journal of the American Medical Association. doi: 10.1001/jama.2026.18380.

Yng23, H.; PLaven-Sigray, P. Ekman, C.J.; Henje, E.; Berglund, A.; Tiger, M.; Beckman, M. Lundberg, J. (2026). Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression: A Randomized Clinical Trial. JAMA Network Open. 2026; 9(5):e2612589. doi:10.1001/jamanetworkopen.2026.12589.

← Back

Thank you for your response. ✨

Rate your experience(required)